BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26259806)

  • 21. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
    Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives (AzDPPYs) as potent T790M mutant form of epidermal growth factor receptor inhibitors.
    Song Z; Jin Y; Ge Y; Wang C; Zhang J; Tang Z; Peng J; Liu K; Li Y; Ma X
    Bioorg Med Chem; 2016 Nov; 24(21):5505-5512. PubMed ID: 27634676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
    Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
    Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
    Hou W; Ren Y; Zhang Z; Sun H; Ma Y; Yan B
    Bioorg Med Chem; 2018 May; 26(8):1740-1750. PubMed ID: 29523467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
    Chang S; Zhang L; Xu S; Luo J; Lu X; Zhang Z; Xu T; Liu Y; Tu Z; Xu Y; Ren X; Geng M; Ding J; Pei D; Ding K
    J Med Chem; 2012 Mar; 55(6):2711-23. PubMed ID: 22339342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
    Ibrahim DA; Abou El Ella DA; El-Motwally AM; Aly RM
    Eur J Med Chem; 2015 Sep; 102():115-31. PubMed ID: 26256032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
    Hao Y; Wang X; Zhang T; Sun D; Tong Y; Xu Y; Chen H; Tong L; Zhu L; Zhao Z; Chen Z; Ding J; Xie H; Xu Y; Li H
    J Med Chem; 2016 Aug; 59(15):7111-24. PubMed ID: 27396610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.
    Zhang Y; Lv H; Luo L; Xu Y; Pan Y; Wang Y; Lin H; Xiong J; Guo P; Zhang J; Li X; Ye F
    Eur J Med Chem; 2018 Sep; 157():1300-1325. PubMed ID: 30195240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C-2 (E)-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFR
    Song A; Zhang J; Ge Y; Wang C; Meng Q; Tang Z; Peng J; Liu K; Li Y; Ma X
    Bioorg Med Chem; 2017 May; 25(10):2724-2729. PubMed ID: 28385595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor.
    Bugge S; Kaspersen SJ; Larsen S; Nonstad U; Bjørkøy G; Sundby E; Hoff BH
    Eur J Med Chem; 2014 Mar; 75():354-74. PubMed ID: 24556149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors.
    Lei H; Fan S; Zhang H; Liu YJ; Hei YY; Zhang JJ; Zheng AQ; Xin M; Zhang SQ
    Eur J Med Chem; 2020 Jan; 186():111888. PubMed ID: 31787359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties.
    Xu S; Xu T; Zhang L; Zhang Z; Luo J; Liu Y; Lu X; Tu Z; Ren X; Ding K
    J Med Chem; 2013 Nov; 56(21):8803-13. PubMed ID: 24124898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment.
    Cui Z; Chen S; Wang Y; Gao C; Chen Y; Tan C; Jiang Y
    Eur J Med Chem; 2017 Aug; 136():372-381. PubMed ID: 28525838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing a 4,5,6,7-tetrahydrothieno [3,2-c]pyridine as potent EGFR inhibitors.
    Li Y; Chang Y; Fu J; Ding R; Zhang L; Liang T; Liu Y; Liu Y; Hu J
    Eur J Med Chem; 2021 Dec; 226():113845. PubMed ID: 34534838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors.
    Ghorab MM; Alsaid MS; Soliman AM; Al-Mishari AA
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):67-73. PubMed ID: 29098904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
    Han C; Huang Z; Zheng C; Wan L; Lai Y; Peng S; Ding K; Ji H; Zhang Y
    Eur J Med Chem; 2013 Aug; 66():82-90. PubMed ID: 23792318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFR
    Yu L; Huang M; Xu T; Tong L; Yan XE; Zhang Z; Xu Y; Yun C; Xie H; Ding K; Lu X
    Eur J Med Chem; 2017 Jan; 126():1107-1117. PubMed ID: 28033579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.
    Lv PC; Zhou CF; Chen J; Liu PG; Wang KR; Mao WJ; Li HQ; Yang Y; Xiong J; Zhu HL
    Bioorg Med Chem; 2010 Jan; 18(1):314-9. PubMed ID: 19914835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
    Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
    Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors.
    Fischer T; Krüger T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2708-2712. PubMed ID: 28478927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.